Galectin Therapeutics (GALT) Debt to Equity (2024 - 2025)
Galectin Therapeutics (GALT) recorded quarterly Debt to Equity of -$0.03 in Q3 2025, down 1016.06% quarter-over-quarter from -$0.0 in Q1 2025, and down 683.64% on a YoY basis from $0.01 in Q3 2024.
Galectin Therapeutics (GALT) Debt to Equity (2024 - 2025) Analysis & Trends
Galectin Therapeutics' Debt to Equity history runs 2 years deep, the most recent figure standing at -$0.03 for Q3 2025.
- In Q3 2025, Debt to Equity fell 683.64% year-over-year to -$0.03; the TTM figure through Sep 2025 stood at -$0.03 (down 683.64% YoY), while the FY2024 annual figure was -$0.0, changed N/A from the prior year.
- Debt to Equity was -$0.03 for Q3 2025 at Galectin Therapeutics, down from -$0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.0 in Q1 2025 to a low of -$0.03 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Galectin Therapeutics | 185.83 Mn | 171.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.03 |
| Mar 31, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.00 |